Clinical Trials Browser

Adrenal Cortex Neoplasms, Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT06995872 2026-04-15

Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

Phase 1 Recruiting

34 enrolled

CNS

Neuroblastoma

NCT00083135 2026-04-14

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

Phase 1 Completed

18 enrolled

CNS

Neuroblastoma

NCT00093353 2026-04-14

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

Phase 1 Completed

30 enrolled

CNS

Diarrhea, Neuroblastoma, Drug-Related Side Effects and Adverse Reactions

NCT00295919 2026-04-14

N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma

Phase 1 Completed

80 enrolled

CNS

Neuroblastoma

NCT00509353 2026-04-14

N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma

Phase 1 Completed

26 enrolled

CNS

Neuroblastoma

NCT00646230 2026-04-14

IV Fenretinide

Phase 1 Completed

17 enrolled

CNS

Neuroblastoma

NCT01711554 2026-04-13

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

Phase 1 Active not recruiting

27 enrolled

CNS

Neuroblastoma

NCT07518654 2026-04-08

ThINKK-01

Phase 1 Not yet recruiting

12 enrolled

CNSLymphoidOther hematologic neoplasm

Paroxysmal nonkinesigenic dyskinesia, Leukemia, Neoplasm Metastasis, Neuroblastoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01822652 2026-04-06

GRAIN

Phase 1 Active not recruiting

11 enrolled

CNS

Neuroblastoma, Recurrence

NCT03721068 2026-03-27

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Phase 1 Recruiting

18 enrolled

CNSSarcoma

Gaucher Disease, Neuroblastoma, Osteosarcoma

NCT06041516 2026-03-27

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

Phase 1 Recruiting

70 enrolled

CNSEndocrineNET

Neuroblastoma, Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Clinical Trials

VEGAS

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors

NYMC195

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma

N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma

IV Fenretinide

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

ThINKK-01

GRAIN

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors